AbbVie Inc.
corporate_fare Company Profile
AbbVie Inc. (NYSE:ABBV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 53 items for ABBV at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 12 rated 8 or above. Recent SEC coverage for ABBV spans 8-K, FWP, 424B5, 10-Q.
Recent high-impact activity:
- AbbVie's Atogepant Hits Primary Endpoint in Phase 3 Menstrual Migraine Trial
- AbbVie's Atogepant Hits Phase 3 Goals in Menstrual Migraine, Plans Global Filings
- AbbVie's Etentamig Hits Primary Endpoints in Phase 3 Myeloma Trial
- AbbVie's Etentamig Hits Dual Primary Endpoints in Phase 3 Multiple Myeloma Trial
- AbbVie Closes $10.9B Apogee Deal, Reaffirms 2026 EPS Outlook
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for ABBV, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
Bond Offering Finalized · Proceeds to Fund Apogee Acquisition
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →